07:06 AM EDT, 07/01/2025 (MT Newswires) -- Atai Life Sciences ( ATAI ) and Beckley Psytech said Tuesday that their phase 2b trial of BPL-003, which is intended for patients with treatment-resistant depression, met primary and all secondary endpoints.

According to the results, both 8mg and 12mg single doses of BPL-003 showed rapid and "clinically meaningful reductions" in depressive symptoms.

The drug candidate was also found to be well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, with no drug-related serious adverse events or suicide-related safety signals.

The companies plan to discuss phase 3 development plans with regulators later this year. An open-label extension study is ongoing, with data expected in Q3.

Shares of Atai Life Sciences ( ATAI ) rose more than 6% in recent pre-bell activity Tuesday.

Price: 2.34, Change: +0.15, Percent Change: +6.85